Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro
| Autor: | Kimberly A. Thomas, Susan M. Shea, Philip C. Spinella |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Blood Safety
Immunology 030204 cardiovascular system & hematology Pharmacology Fibrinogen dilutional coagulopathy Hemostatics 03 medical and health sciences 0302 clinical medicine Thrombin medicine Humans Immunology and Allergy Dysfibrinogenemia Hemostatic function fibrinogen concentrate hemostatic capacity Hemostasis Factor VIII pathogen reduction business.industry Sterilization Hematology Blood Coagulation Disorders medicine.disease Blood Coagulation Factors Fibrinogen complex Thromboelastometry Coagulation Cryoprecipitate cryoprecipitate business 030215 immunology medicine.drug |
| Zdroj: | Transfusion |
| ISSN: | 1537-2995 0041-1132 |
| Popis: | Background Fibrinogen concentrates and cryoprecipitate are currently used for fibrinogen supplementation in bleeding patients with dysfibrinogenemia. Both products provide an abundant source of fibrinogen but take greater than 10 min to prepare for administration. Fibrinogen concentrates lack coagulation factors (i.e., factor VIII [FVIII], factor XIII [FXIII], von Willebrand factor [VWF]) important for robust hemostatic function. Cryoprecipitate products contain these factors but have short shelf lives ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text